Kurma Partners

Type

Venture Capital

Status

Active

Location

Paris, France

Total investments

111

Average round size

28M

Portfolio companies

54

Rounds per year

7.40

Lead investments

31

Follow on index

0.51

Exits

9

Stages of investment
SeedEarly Stage VentureLate Stage Venture
Areas of investment
BiotechnologyHealth CareHealth DiagnosticsWellnessGeneticsMedical DeviceMedicalLife SciencePharmaceuticalTherapeutics

Summary

In 2009 was created Kurma Partners, which is appeared as VC. The venture was found in Europe in France. The main office of represented VC is situated in the Paris.

The fund was created by Thierry Laugel. The overall number of key employees were 6.

The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Kurma Partners, startups are often financed by Ysios Capital, Wilco, Bpifrance. The meaningful sponsors for the fund in investment in the same round are Paris-Saclay Seed Fund, Bpifrance, Idinvest Partners. In the next rounds fund is usually obtained by Bpifrance, Life Sciences Partners, Ysios Capital.

The top activity for fund was in 2017. Despite it in 2019 the fund had an activity. The fund is generally included in 2-6 deals every year. The higher amount of exits for fund were in 2018. Comparing to the other companies, this Kurma Partners performs on 19 percentage points less the average number of lead investments. The common things for fund are deals in the range of 10 - 50 millions dollars. Speaking about the real fund results, this VC is 54 percentage points more often commits exit comparing to other organizations.

The fund has no exact preference in some founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - France. Among the most successful fund investment fields, there are Therapeutics, Medical Device. Among the most popular portfolio startups of the fund, we may highlight AM Pharma, Minoryx Therapeutics, Dynacure.

Show more

Investor highlights

Industry focus
Biotech/Life SciencesAgricultureMedtech
Stage focus
SeedSeries CSeries APre-SeedSeries B Show 1 more
Geo focus
AlbaniaAustriaBelgiumBosnia and HerzegovinaBulgaria Show 37 more

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Last fund

Fund size
EUR 160000000
Fund raised date
2022-03-08

Analytics

Total investments
111
Lead investments
31
Exits
9
Rounds per year
7.40
Follow on index
0.51
Investments by industry
  • Health Care (72)
  • Biotechnology (70)
  • Therapeutics (32)
  • Medical (30)
  • Pharmaceutical (29)
  • Show 26 more
Investments by region
  • France (69)
  • Denmark (5)
  • Netherlands (10)
  • Switzerland (9)
  • Spain (7)
  • Show 4 more
Peak activity year
2021

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
8
Avg. valuation at time of investment
9M
Group Appearance index
0.96
Avg. company exit year
8
Strategy success index
0.30

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Horama 21 Jul 2021 Biotechnology, Genetics, Life Science, Neuroscience Early Stage Venture 38M Ile-de-France, Paris, France
SmartCatch 17 May 2021 Health Care, Health Diagnostics, Medical Device, Therapeutics Seed 3M Midi-Pyrenees, Toulouse, France

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.